The immunobiological development of human bone marrow mesenchymal stem cells in the course of neuronal differentiation

Cellular Immunology

Volumn 244, Issue 1, 2006, Pages 19-32

  Liu, Chen Tao ^a   Yang, Yu Jia ^a   Yin, Fei ^a   Wang, Xia ^a   Yu, Xiao He ^a   Wang, Qing Hong ^a   Wang, Xiao Li ^a   Xie, Min ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Immunogenic molecules; Immunomodulatory; Mesenchymal stem cells; Neuronal differentiation

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MITOGENIC AGENT;

ARTICLE; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL INTERACTION; CELL LINEAGE; HUMAN; HUMAN CELL; IMMUNOBIOLOGY; IMMUNOMODULATION; IN VITRO STUDY; MESENCHYMAL STEM CELL; NERVE CELL DIFFERENTIATION; NORMAL HUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD40; ANTIGENS, CD86; BLOTTING, WESTERN; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL PROLIFERATION; HISTOCOMPATIBILITY ANTIGENS; HUMANS; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOCYTES; MESENCHYMAL STEM CELLS; NEURONS;

EID: 34247486165     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2007.02.003     Document Type: Article

References (34)

1. Moriscot C., de Fraipont F., Richard M.J., Marchand M., Savatier P., Bosco D., Favrot M., and Benhamou P.Y. Human bone marrow mesenchymal stem cells can express insulin and key transcription factors of the endocrine pancreas developmental pathway upon genetic and/or microenvironmental manipulation in vitro. Stem Cells 23 4 (2005) 594-603
2. Sato Y., Araki H., Kato J., Nakamura K., Kawano Y., Kobune M., Sato T., Miyanishi K., Takayama T., Takahashi M., Takimoto R., Iyama S., Matsunaga T., Ohtani S., Matsuura A., Hamada H., and Niitsu Y. Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood 106 2 (2005) 756-763
3. Yang J., Zhou W., Zheng W., Ma Y., Lin L., Tang T., Liu J., Yu J., Zhou X., and Hu J. Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction. Cardiology 107 1 (2006) 17-29
4. Dunbar G.L., Sandstrom M.I., Rossignol J., and Lescaudron L. Neurotrophic enhancers as therapy for behavioral deficits in rodent models of Huntington's disease: use of gangliosides, substituted pyrimidines, and mesenchymal stem cells. Behav Cogn Neurosci. Rev. 5 2 (2006) 63-79
5. Tsuchida H., Hashimoto J., Crawford E., Manske P., and Lou J. Engineered allogeneic mesenchymal stem cells repair femoral segmental defect in rats. J. Orthop. Res. 21 (2003) 44-53
6. Cizkova D., Rosocha J., Vanicky I., Jergova S., and Cizek M. Transplants of human mesenchymal stem cells improve functional recovery after spinal cord injury in the rat. Cell Mol. Neurobiol. 26 7-8 (2006) 1167-1180
7. Lee S.T., Chu K., Park J.E., Lee K., Kang L., Kim S.U., and Kim M. Intravenous administration of human neural stem cells induces functional recovery in Huntington's disease rat model. Neurosci. Res. 52 3 (2005) 243-249
8. Parati E.A., Bez A., Ponti D., Sala S., Pozzi S., and Pagano S.F. Neural stem cells. Biological features and therapeutic potential in Parkinson's disease. J. Neurosurg. Sci. 47 1 (2003) 8-17
9. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276 (1997) 71-74
10. Pittenger M.F., Mackay A.M., Beck S.C., et al. Multi-lineage potential of adult human mesenchymal stem cells. Science 284 (1999) 143-147
11. Fuchs J.R., Hannouche D., Terada S., Vacanti J.P., and Fauza D.O. Fetal tracheal augmentation with cartilage engineered from bone marrowderived mesenchymal progenitor cells. J. Pediatr. Surg. 38 (2003) 984-987
12. Saito T., Kuang J.Q., Lin C.C., and Chiu R.C. Transcoronary implantation of bone marrow stromal cells ameliorates cardiac function after myocardial infarction. J. Thorac. Cardiovasc. Surg. 126 (2003) 114-123
13. Sanchez-Ramos J.R. Neural cells derived from adult bone marrow and umbilical cord blood. J. Neurosci Res. 69 6 (2002) 880-893
14. Hofstetter C.P., Schwarz E.J., Hess D., et al. Marrow stromal cells formguiding strands in the injured spinal cord and promote recovery. Proc. Natl. Acad. Sci. USA 99 (2002) 2199-2204
15. Wu S., Suzuki Y., Ejiri Y., et al. Bone marrow stromal cells enhance differentiation of cocultured neurosphere cells and promote regeneration of injured spinal cord. J. Neurosci. Res. 72 (2003) 343-351
16. Deans R.J., and Moseley A.-M. Mesenchymal stem cells: Biology and potential clinical uses. Exp. Hematol. 28 (2000) 875-884
17. Tse W.T., Pendleton J.D., Beyer W., Tgalka M.C., and Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75 (2003) 389-397
18. Bartholomew A., Sturgeon C., Siatskas M., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30 1 (2002) 42-48
19. Kim D.-W., Chung Y.-J., Kim T.-G., and Oh I.-H. Cotransplantation of third party mesenchymal stromal cells can alleviate singledonor predominance and increase engraftment from double cord transplantation. Blood 103 (2004) 1941-1948
20. Liu H., Kemeny D.M., Heng B.C., et al. The immunogenicity and immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells. J. Immunol. 176 5 (2006) 2864-2871
21. Barker R.A., and Widner H. Immune problems in central nervous system cell therapy. NeuroRx 1 4 (2004) 472-481
22. Brevig T., Holgersson J., and Widner H. Xenotransplantation for CNS repair: immunological barriers and strategies to overcome them. Trends Neurosci. 23 (2000) 337-344
23. Hickey W.H. Basic principles of immunological surveillance of the normal central nervous system. Glia 36 (2001) 118-124
24. Wong R.K., Hagg E.U., Rabie A.B., et al. Bone induction in clinical orthodontics: a review. Int. J. Adult Orthodon. Orthognath. Surg. 17 2 (2002) 140-149
25. Byrne S.N., and Halliday G.M. High levels of Fas ligand and MHC class II in the absence of CD80 or CD86 expression and a decreased CD4+ T cell Infiltration, enables murine skin tumours to progress. Cancer Immunol. Immunother. 52 6 (2003) 396-402
26. Modo M., Mellodew K., and Rezaie P. In vitro expression of major histocompatibility class I and class II antigens by conditionally immortalized murine neural stem cells. Neurosci. Lett. 337 2 (2003) 85-88
27. Le Blanc K., Tammik C., Rosendahl K., Zetterberg E., and Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 31 10 (2003) 890-896
28. Odeberg J., Piao J.H., Samuelsson E.B., Falci S., and Akesson E. Low immunogenicity of in vitro-expanded human neural cells despite high MHC expression. J. Neuroimmunol. 161 1-2 (2005) 1-11
29. Manzotti C.N., Liu M.K., Burke F., Dussably L., Zheng Y., and Sansom D.M. Integration of CD28 and CTLA-4 function results in differential responses of T cells to CD80 and CD86. Eur. J. Immunol. 36 6 (2006) 1413-1422
30. Klyushnenkova E., Mosca J.D., Zernetkina V., et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J. Biomed. Sci. 12 1 (2005) 47-57
31. Bartholomew A., Sturgeon C., Siatskas M., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30 1 (2002) 42-48
32. Di Nicola M., Carlo-Stella C., Magni M., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99 10 (2002) 3838-3843
33. Eliopoulos N., Stagg J., Lejeune L., Pommey S., and Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 106 13 (2005) 4057-4065
34. Nauta A.J., Westerhuis G., Kruisselbrink A.B., Lurvink E.G., Willemze R., and Fibbe W.E. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a non-myeloablative setting. Blood 108 6 (2006) 2114-2120